Lotiglipron dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Lotiglipron worked. In 901 people, average blood sugar fell by up to 1.44 points and weight fell by up to 7.47 percent, against 1.84 percent on a dummy pill. The study was stopped early for safety anyway.
Evidence grade for Lotiglipron: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 registered with no result. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 registered with no result
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Lotiglipron was a Pfizer pill meant to do what Ozempic does, without a shot. It worked. The study was stopped early for safety, and the drug was dropped. You cannot get it.
What people take it for
- Weight loss from a pill instead of a weekly shot.
- Lower blood sugar in type 2 diabetes.
What studies in people showed
901 people took it, some with type 2 diabetes and some with obesity. Average blood sugar fell by up to 1.44 points, against 0.07 on a dummy pill. Weight fell by up to 7.47 percent, against 1.84 percent on the dummy pill. Most people on the higher doses never even reached their target dose. Then the study was stopped early for safety, after a routine review. The summary does not say what the safety problem was.
What people report
Reports, not study results
The good
- In the study, people lost weight and their blood sugar dropped at every dose.
The bad
- Nausea was common. It reached 60.6 percent at the top obesity dose, against 12.5 percent on the dummy pill.
- The study was stopped early for safety.
Where these come from: Everything here is from the one study on this page. There are no forum reports, since the drug was never sold.
My bottom line
This one worked and still got pulled. That is the lesson. A drug that works is not the same as a drug that is safe, and anything sold online under this name is not the real thing.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Lotiglipron has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
- Blood sugar and insulinno headcount stated · 1 study
34 of the 36 indexed goals have no study of any kind behind Lotiglipron
No study in people, animals or cells on this page reports a result for these. That does not prove Lotiglipron does nothing for them. It does mean anything you have heard about Lotiglipron and one of these did not come from a study cited here.
Show full evidence
What is Lotiglipron?
Lotiglipron worked. In 901 people, average blood sugar fell by up to 1.44 points and weight fell by up to 7.47 percent, against 1.84 percent on a dummy pill. The study was stopped early for safety anyway.
Lotiglipron shows why a GLP-1 pill was harder than it looked. The problem was never whether it worked.
Pfizer tested it in 901 people. Some had type 2 diabetes and some had obesity. In the diabetes group, average blood sugar fell at every dose, by up to 1.44 points, against 0.07 on a dummy pill. In the obesity group, weight fell at every dose, by up to 7.47 percent, against 1.84 percent on the dummy pill. Those are real numbers from a large, well-run study.
The study was stopped early for safety, after a routine review of the data. The planned analysis was changed before anyone knew who got what. The drug was dropped.
One detail is worth noticing. Most people put on the higher doses never reached their target dose. The drug still did all that.
How does Lotiglipron work?
Lotiglipron is a small chemical pill that switches on the GLP-1 receptor, the same target as Ozempic. Semaglutide is a protein. It needs a helper ingredient to survive the stomach as a pill. A small chemical like this one is absorbed the normal way, which is the whole business appeal. It grabs the receptor at a different spot from the body's own hormone, because something small enough to swallow cannot copy a big protein's grip. After that, the effects are the same. It helps the body release insulin when blood sugar is high, lowers a hormone that raises blood sugar, slows the stomach and cuts appetite.
What have studies in people found about Lotiglipron?
One large study that clearly worked for both diabetes and obesity, and was stopped early for safety before it could finish.
- 901 people took it, in separate groups for type 2 diabetes and obesity.
- Average blood sugar fell at every dose by week 16, by up to 1.44 points, against 0.07 on a dummy pill.
- Weight fell at every dose by week 20, by up to 7.47 percent, against 1.84 percent on a dummy pill.
- Most people put on the higher doses never reached their target dose. So these results came at less than the planned amount.
- Stomach side effects were the main problem and got worse with dose. Nausea hit 60.6 percent at the top obesity dose, against 12.5 percent on the dummy pill.
- The study was stopped early for safety, and the analysis was changed before anyone knew who got what. That is what a drug company does when a warning sign shows up mid-study.
What this does not tell you: Stopping early changes what the results mean. They come from a study that did not run to plan. The analysis was changed partway, and many people got less drug than planned. So read them as a strong hint, not the final word. Some reports say the reason for stopping was a rise in liver enzymes. The study summary does not say that, so this page only says it was stopped for safety. The nausea numbers matter on their own too. 60.6 percent at the top dose is a problem people have to live with, whatever the safety issue was.
The state of the research
Look at the GLP-1 pills that are small chemicals as a group, and one thing stands out. Whether they worked was not the problem. Lotiglipron cut average blood sugar by up to 1.44 points in 901 people. It cut weight by up to 7.47 percent, against 1.84 percent on a dummy pill. Its study was stopped early for safety. TERN-601 led to more weight loss at every dose in its first study, and at 500 mg and up in its second. It was dropped after three people had liver enzyme rises that pointed to possible liver damage. Orforglipron was approved. So two of three serious drugs were stopped over the liver, not because they failed to work. That applies to the whole drug type. A swallowed chemical reaches the liver first, at the highest level it will hit anywhere in the body. That does not make every GLP-1 pill dangerous. It does mean liver checks are a real part of the story, not fine print.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 1 source here is a study in people.
- Study in people · done in people1100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- A small molecule. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Designed for once-daily oral dosing. No specific half-life figure was resolved in the sources loaded.
No amino acid sequence is on file for Lotiglipron, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2025Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging study
Lotiglipron worked on blood sugar and weight, and it was stopped anyway for safety. 901 people took at least one dose, 512 with type 2 diabetes and 389 with obesity. Some got a dummy pill. Average blood sugar fell by up to 1.44 points against almost nothing on the dummy pill. Weight fell by up to 7.47 percent against 1.84 percent. The study was stopped early for safety after a routine review. Nausea reached 60.6 percent at the highest obesity dose. Most people never reached their target dose.
Phase 2, randomised, double-blind, placebo-controlled, dose-ranging. 901 participants treated with at least one dose, 512 in the type 2 diabetes cohort and 389 in the obesity cohort. Terminated early for safety reasons after routine data and monitoring review, with planned analyses modified before unblinding. HbA1c fell across all doses at week 16 (p < 0.0001), by up to 1.44 percent (90% CI minus 1.63 to minus 1.26) against minus 0.07 percent on placebo. Weight fell across all doses at week 20 (p < 0.01), by up to 7.47 percent (90% CI minus 8.50 to minus 6.43) against minus 1.84 percent on placebo. Most participants on higher doses did not reach their target maintenance dose. Nausea ranged from 4 percent on placebo to 28.8 percent at 80 mg in diabetes, and 12.5 percent on placebo to 60.6 percent at 200 mg in obesity.
Common questions
Has Lotiglipron been tested in people?
Not in a completed trial cited here. 1 registered with no result. Lotiglipron worked. In 901 people, average blood sugar fell by up to 1.44 points and weight fell by up to 7.47 percent, against 1.84 percent on a dummy pill. The study was stopped early for safety anyway.
What is the Lotiglipron dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 registered with no result
Is Lotiglipron FDA-approved?
Never approved. The mid-stage studies were stopped early for safety reasons, and work on the drug ended.
Did lotiglipron work?
Yes, and that is the point of this page. In 901 people it cut average blood sugar by up to 1.44 points, and weight by up to 7.47 percent against 1.84 percent on a dummy pill. It did that even though most people on the higher doses never reached their target dose. It was stopped for safety, not because it did not work.
Why was it stopped?
The published record says the study was stopped early for safety, after a routine review of the data. The planned analysis was changed before anyone knew who got what. The summary does not name the safety problem, so this site does not either. What we can say is that a second GLP-1 pill of the same type, TERN-601, was dropped after liver enzyme rises that pointed to possible liver damage.
Does this mean oral GLP-1 pills are unsafe?
No. Orforglipron was approved, so the idea is not doomed. It does mean the liver is the thing to watch. A swallowed chemical reaches the liver first, at the highest level it will hit anywhere in the body. And two of the three serious drugs of this type were stopped over safety, not because they did not work.